Replies to post #194944 on Avid Bioservices Inc (CDMO)

[Robert C Jonson]

"Point is it was not a smart thing to say and I am sure CSM lawyers were happy to hear it along with any BP who might actually be in "active" discussions"

Disagree.

Everyone knows a company which has never brought a drug to market is inexperienced in the approval process, so no great revelation there. Bringing RG aboard under the circumstances was a great, if not brilliant, move.

[corporalagarn]

Fingers crossed.

All of the following took place under the current management team and, in my opinion, is why we are at where we are.

The $50 million dollar DIOS hoax that was perpetrated on Wall Street by this crew, May, 2007.

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=266038

The reverse split to stay Nasdaq compliant, October, 2009.

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=416393

The Stason "deal", May 2010.

http://www.biospace.com/news_story.aspx?StoryID=178872

The 80%, one day drop in the pps due to "major discrepancies"

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=708954

Outstanding shares on September 30, 2009, 45m. Outstanding shares current, 180m. Dilution by a factor of 4 and no end in sight.

Insider ownership, less than one percent.

Chairman of the Board of Directors.

http://ir.peregrineinc.com/directors.cfm

Most of these things are in the past but they all matter. It is how the company is judged. Putting out a pr about bird flu or ebola when they are hot to get a quick, temporary bump in the share price is not viewed in a positive light. Mentioning that you are in partnership talks for over ten years and not having anything to show for it is not good. Switching from King to Worsley in mentioning partners does nothing. King is likely too embarrassed to say it any more. Good for him.

Maybe this post should be a sticky that people can be referred to anytime somebody asks why another company is where it is at in relation to PPHM.

I realize that none of the above matters to many here, but it matters to Wall Street and institutional investors. It is why the pps is what it is and the institutional holdings are what they are. The pps means nothing to many here, that's fine. It does mean something to me. I am currently slightly under water on this stock and I would like to make some money on it. I guess 2017 is our year.

[biopharm]

Frustrated, you are completely wrong.

I don't know how many times this needs to be explained and makes me wonder what the point is to keep bringing up Garnick and why he is not an employee vs his current status = consultant, which is basically an independent contractor for all purposes. There are advantages to both Peregrine "AND" Robert Garnick to have it the way it is and hopefully this will be the last time it needs to be explained: I'll just point out one of the many advantages...

You can also take advantage of many business-related tax deductions that are not available to employees. When you're an IC, you can deduct from your taxable income any necessary expenses related to your business, as long as they are reasonable in amount and ordinarily incurred by businesses of your type. This may include, for example, office expenses (including costs associated with a home office), travel expenses, entertainment and meal expenses, cable TV and magazine expenses, equipment and insurance costs, and much more.

http://www.nolo.com/legal-encyclopedia/being-consultant-freelancer-or-contractor-29593.html

Frustrated, you do realize Rob Garnick has his own business... right? : )

Just as tax inversions are being sought for tax benefits, the same is said for all consultants and the tax benefits they enjoy. Peregrine also saves taxes as well and they are able to pay Garnick his proper worth, which just may be priceless after all is said and done and the first of many FDA approvals are achieved.

Now back to this microscope... unbelievable, within hours of Bavituximab I think I see changes at the cellular level.